Pulmonary toxicity associated with fludarabine monophosphate

Paul G. Hurst; Michael P. Habib; Harinder Garewal; Marlene Bluestein; Maria Paquin; Bernard R. Greenberg

doi:10.1007/BF00203548

Pulmonary toxicity associated with fludarabine monophosphate

Paul G. Hurst, Michael P. Habib, Harinder Garewal, Marlene Bluestein, Maria Paquin, Bernard R. Greenberg

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Fludarabine monophosphate (FAMP), the 2-fluoro, 5′phosphate derivative of 9-β-D-arabinofuranosyl adenine (ara-A), is a purine nucleoside antimetabolite presently undergoing clinical testing for the treatment of a variety of malignancies including lymphoproliferative disorders and acute leukemia. We report a case of diffuse interstitial pneumonitis during treatment of chronic lymphocytic leukemia with FAMP. This resolved quickly with high dose steroids, recurred with steroid withdrawal, and abated with further steroid therapy. To our knowledge, this is the first reported case of fludarabine monophosphate associated pulmonary toxicity.

Original language	English (US)
Pages (from-to)	207-210
Number of pages	4
Journal	Investigational New Drugs
Volume	5
Issue number	2
DOIs	https://doi.org/10.1007/BF00203548
State	Published - Jun 1987
Externally published	Yes

Keywords

drug induced pulmonary disease
fludarabine monophosphate

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00203548

Cite this

@article{cd14183ad80747839b0d24dff2f823ef,

title = "Pulmonary toxicity associated with fludarabine monophosphate",

abstract = "Fludarabine monophosphate (FAMP), the 2-fluoro, 5′phosphate derivative of 9-β-D-arabinofuranosyl adenine (ara-A), is a purine nucleoside antimetabolite presently undergoing clinical testing for the treatment of a variety of malignancies including lymphoproliferative disorders and acute leukemia. We report a case of diffuse interstitial pneumonitis during treatment of chronic lymphocytic leukemia with FAMP. This resolved quickly with high dose steroids, recurred with steroid withdrawal, and abated with further steroid therapy. To our knowledge, this is the first reported case of fludarabine monophosphate associated pulmonary toxicity.",

keywords = "drug induced pulmonary disease, fludarabine monophosphate",

author = "Hurst, {Paul G.} and Habib, {Michael P.} and Harinder Garewal and Marlene Bluestein and Maria Paquin and Greenberg, {Bernard R.}",

year = "1987",

month = jun,

doi = "10.1007/BF00203548",

language = "English (US)",

volume = "5",

pages = "207--210",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Pulmonary toxicity associated with fludarabine monophosphate

AU - Hurst, Paul G.

AU - Habib, Michael P.

AU - Garewal, Harinder

AU - Bluestein, Marlene

AU - Paquin, Maria

AU - Greenberg, Bernard R.

PY - 1987/6

Y1 - 1987/6

N2 - Fludarabine monophosphate (FAMP), the 2-fluoro, 5′phosphate derivative of 9-β-D-arabinofuranosyl adenine (ara-A), is a purine nucleoside antimetabolite presently undergoing clinical testing for the treatment of a variety of malignancies including lymphoproliferative disorders and acute leukemia. We report a case of diffuse interstitial pneumonitis during treatment of chronic lymphocytic leukemia with FAMP. This resolved quickly with high dose steroids, recurred with steroid withdrawal, and abated with further steroid therapy. To our knowledge, this is the first reported case of fludarabine monophosphate associated pulmonary toxicity.

AB - Fludarabine monophosphate (FAMP), the 2-fluoro, 5′phosphate derivative of 9-β-D-arabinofuranosyl adenine (ara-A), is a purine nucleoside antimetabolite presently undergoing clinical testing for the treatment of a variety of malignancies including lymphoproliferative disorders and acute leukemia. We report a case of diffuse interstitial pneumonitis during treatment of chronic lymphocytic leukemia with FAMP. This resolved quickly with high dose steroids, recurred with steroid withdrawal, and abated with further steroid therapy. To our knowledge, this is the first reported case of fludarabine monophosphate associated pulmonary toxicity.

KW - drug induced pulmonary disease

KW - fludarabine monophosphate

UR - http://www.scopus.com/inward/record.url?scp=0023088253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023088253&partnerID=8YFLogxK

U2 - 10.1007/BF00203548

DO - 10.1007/BF00203548

M3 - Article

C2 - 2443463

AN - SCOPUS:0023088253

SN - 0167-6997

VL - 5

SP - 207

EP - 210

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Pulmonary toxicity associated with fludarabine monophosphate

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this